196 related articles for article (PubMed ID: 25690670)
1. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.
Stremitzer S; Zhang W; Yang D; Ning Y; Stintzing S; Sebio A; Sunakawa Y; Yamauchi S; Matsusaka S; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Cancer; 2015 Jun; 121(11):1898-905. PubMed ID: 25690670
[TBL] [Abstract][Full Text] [Related]
2. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
Volz NB; Stintzing S; Zhang W; Yang D; Ning Y; Wakatsuki T; El-Khoueiry RE; Li JE; Kardosh A; Loupakis F; Cremolini C; Falcone A; Scherer SJ; Lenz HJ
Pharmacogenomics J; 2015 Feb; 15(1):69-76. PubMed ID: 25069475
[TBL] [Abstract][Full Text] [Related]
3. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.
Stremitzer S; Zhang W; Yang D; Ning Y; Stintzing S; Sunakawa Y; Sebio A; Yamauchi S; Matsusaka S; Parekh A; Barzi A; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Ann Oncol; 2015 Aug; 26(8):1728-33. PubMed ID: 25957329
[TBL] [Abstract][Full Text] [Related]
4. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.
Stremitzer S; Sunakawa Y; Zhang W; Yang D; Ning Y; Stintzing S; Sebio A; Yamauchi S; Matsusaka S; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Pharmacogenomics J; 2015 Dec; 15(6):521-9. PubMed ID: 25752522
[TBL] [Abstract][Full Text] [Related]
5. Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.
Makhoul I; Todorova VK; Siegel ER; Erickson SW; Dhakal I; Raj VR; Lee JY; Orloff MS; Griffin RJ; Henry-Tillman RS; Klimberg S; Hutchins LF; Kadlubar SA
PLoS One; 2017; 12(1):e0168550. PubMed ID: 28045923
[TBL] [Abstract][Full Text] [Related]
6. Microscopic biliary and perineural invasion and clinical outcome after neoadjuvant bevacizumab-based chemotherapy and liver resection in patients with colorectal liver metastases.
Stift J; Graf A; Schwarz C; Tamandl D; Starlinger P; Herac M; Beer A; Wrba F; Bodingbauer M; Kaczirek K; Stremitzer S
Eur J Surg Oncol; 2018 Jan; 44(1):139-147. PubMed ID: 29203074
[TBL] [Abstract][Full Text] [Related]
7. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants and response to cancer treatments.
Warusavitarne J; Stebbing J; Faiz O
Cancer; 2015 Jun; 121(11):1735-6. PubMed ID: 25690531
[No Abstract] [Full Text] [Related]
9. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
[TBL] [Abstract][Full Text] [Related]
10. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism in a VEGF-independent angiogenesis gene ANGPT1 and overall survival of colorectal cancer patients after surgical resection.
Dai J; Wan S; Zhou F; Myers RE; Guo X; Li B; Fu X; Palazzo JP; Dou K; Yang H; Xing J
PLoS One; 2012; 7(4):e34758. PubMed ID: 22496856
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
[TBL] [Abstract][Full Text] [Related]
15. Genetic Variants of
Gaibar M; Galán M; Romero-Lorca A; Antón B; Malón D; Moreno A; Fernández-Santander A; Novillo A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573134
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
Formica V; Palmirotta R; Del Monte G; Savonarola A; Ludovici G; De Marchis ML; Grenga I; Schirru M; Guadagni F; Roselli M
Int J Colorectal Dis; 2011 Feb; 26(2):143-51. PubMed ID: 21188390
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases.
Stift J; Graf A; Neudert B; Herac M; Woeran K; Tamandl D; Laengle J; Schwarz C; Wrba F; Kaczirek K; Stremitzer S
HPB (Oxford); 2022 Jan; 24(1):40-46. PubMed ID: 34158230
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer.
Kim JG; Chae YS; Sohn SK; Cho YY; Moon JH; Park JY; Jeon SW; Lee IT; Choi GS; Jun SH
Clin Cancer Res; 2008 Jan; 14(1):62-6. PubMed ID: 18172253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]